In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Promed Of India To Spend $27.5 Million Expanding Next Three Years

This article was originally published in PharmAsia News

Executive Summary

India's Promed Group says it plans to make a large investment over the next three years to expand its overseas market and the capacity to deal with it. President Deepak Bahri said at a news conference the company plans to pour $27.5 million into the expansion, nearly half of it to double the capacity of one of its production plants. Other plants would be built in developed countries if the firm gets approvals from regulators, he said. Bahri said Promed expects to get European Union clearance for his plant yet this year and U.S. FDA approval next year. Promed plans to introduce as many as a dozen generics a year. (Click here for more



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts